| Literature DB >> 34341841 |
Luis Javier González1, Pedro E Encinosa Guzmán2, Wendy Machado3, Satomy Pousa3, Alejandro Leyva4,5, Ana Laura Cano Arguelles2, Gleysin Cabrera3, Luis Ariel Espinosa3, Rubén Parra3, Rachel Hernández3, Yamil Bello Soto2, Frank L Ledesma2, Marisdania Joglar2, Osmany Guirola6, Louise Ulrich Kurt7, Paulo C Carvalho7, Ania Cabrales8, Hilda Garay8, Vladimir Besada3, Rosario Durán4,5, Toshifumi Takao9, Mario Pablo Estrada2, Alina Rodríguez-Mallon10.
Abstract
A peptide from the P0 acidic ribosomal protein (pP0) of ticks conjugated to keyhole limpet hemocyanin from Megathura crenulata has shown to be effective against different tick species when used in host vaccination. Turning this peptide into a commercial anti-tick vaccine will depend on finding the appropriate, technically and economically feasible way to present it to the host immune system. Two conjugates (p64K-Cys1pP0 and p64K-βAla1pP0) were synthesized using the p64K carrier protein from Neisseria meningitidis produced in Escherichia coli, the same cross-linking reagent, and two analogues of pP0. The SDS-PAGE analysis of p64K-Cys1pP0 showed a heterogeneous conjugate compared to p64K-βAla1pP0 that was detected as a protein band at 91kDa. The pP0/p64K ratio determined by MALDI-MS for p64K-Cys1pP0 ranged from 1 to 8, being 3-5 the predominant ratio, while in the case of p64K-βAla1pP0 this ratio was 5-7. Cys1pP0 was partially linked to 35 out of 39 Lys residues and the N-terminal end, while βAla1pP0 was mostly linked to the six free cysteine residues, to the N-terminal end, and, in a lesser extent, to Lys residues. The assignment of the conjugation sites and side reactions were based on the identification of type 2 peptides. Rabbit immunizations showed the best anti-pP0 titers and the highest efficacy against Rhipicephalus sanguineus ticks when the p64K-Cys1pP0 was used as vaccine antigen. The presence of high molecular mass aggregates observed in the SDS-PAGE analysis of p64K-Cys1pP0 could be responsible for a better immune response against pP0 and consequently for its better efficacy as an anti-tick vaccine. Graphical abstract.Entities:
Keywords: Anti-tick vaccine; Conjugation sites; Cross-linked peptides; Mass spectrometry; P0; p64K
Mesh:
Substances:
Year: 2021 PMID: 34341841 PMCID: PMC8328535 DOI: 10.1007/s00216-021-03569-0
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.478
Fig. 1Strategies for the synthesis of two vaccine candidates against ticks, here named p64K-Cys1pP0 (a) and p64K-βAla1pP0 (b). Both strategies are based on the chemical conjugation of the recombinant p64K carrier protein from N. meningitidis and two variants of a peptide from the tick acidic ribosomal P0 protein (Cys1-pP0 and Mal-βAla1-pP0) using the bmps as the heterobifunctional cross-linker reagent. Mal- means a maleimide group incorporated at the N-terminal end of the pP0 peptide during the solid-phase peptide synthesis. The ellipse indicates the sequence of the pP0 peptide (NH2–282AAGGGAAAAKPEESKKEEAK301–CONH2)
Fig. 2(a) SDS-PAGE analysis under reducing conditions of the synthetized conjugates p64K-Cys1pP0 and p64K-βAla1pP0. Lane 1: molecular weight markers; lane 2: recombinant p64K carrier protein from N. meningitidis; lane 3: p64K-Cys1pP0; and lane 4: p64K-βAla1pP0. The MALDI-MS spectra shown in (b) and (c) correspond to the p64K-Cys1pP0 and p64K-βAla1pP0, respectively. The broken lines indicate the additions of several units of Cys1pP0 and βAla1pP0 to the p64K protein in the resultant conjugates. The number of units of pP0 (1-8) added in the resultant conjugates are indicated above each signals. +(Cys1pP0)1+ and +(Cys1pP0)2+ correspond to singly and doubly charged ions of p64K-Cys1pP0, while +(βAla1pP0)1+ and +(βAla1pP0)2+ correspond to the same information for p64K-βAla1pP0. Asterisks in (c) correspond to probably further additions (8-9) of βAla1pP0 to the amino groups of p64K carrier protein
Fig. 3(a) Conjugation site assignment in p64K-Cys1pP0. Dark- and gray-solid bars indicate the number of conjugation sites and their corresponding MS/MS spectra assigned to type 2 peptides by the evaluated software (Kojak [28], StavroX [29], and pLink2 [27]), respectively. (b) The Venn diagram shows the overlapping results of the evaluated software for the assignment of MS/MS spectra to type 2 peptides containing the conjugation sites in p64K-Cys1pP0. (c) Conjugation site assignments in p64K-βAla1pP0. Light-gray bars indicate the number of MS/MS spectra assigned by software to type 2 peptides containing the conjugation sites. Dark bars indicate the number of conjugation sites identified by the evaluated software in p64K-βAla1pP0. (d) The Venn diagram with overlapping MS/MS spectra assigned to intermolecular type 2 peptides by the evalauted software. The shaded areas in both Venn diagrams are labeled with the number of MS/MS spectra assigned to type 2 peptides as well as the percentage they represent
Fig. 4(a) MS/MS spectrum assigned by pLink2 software to a type 2 peptide (m/z 772.6390, 4+) in p64K-Cys1pP0 composed by a proteolytic peptide of p64K [258-271] linked through the side chain of K262 to Cys1pP0(1-16). “C” in red means carbamidomethyl Cys residue. (b) The MS/MS spectrum of a signal detected at m/z 542.0011, 4+ assigned by pLink2 to a type 2 peptide [457-462]-βAla1pP0 (1-16) containing the Cys458 as a conjugation site in p64K. The solid arrows shown in the MS/MS spectra of [258-271]-Cys1pP0 (1-16) (a) and [457-462]-βAla1pP0(1-16) (b) were assigned as y”5β and y”5α, respectively, and they correspond to a diagnostic ion (m/z =589.283)
Fig. 5(a) Specific antibody responses obtained in immunized rabbits against pP0 and p64K. The Y axes are in a logarithmic scale. Each point represents the antibody titer of one animal inside the group and the line represents the geometric mean of antibody titers in the group. Asterisks represent statistically significant differences in the antibody titers between immunized groups (t-test, *P<0.05). (b) Fold change of cytokine expression in PBMCs of vaccinated rabbits over non-vaccinated rabbits. Asterisks represent statistical significance (p-value) calculated using the Wilcoxon signed-rank test (*P<0.05)
Efficacy of the p64K-Cys1pP0 and p64K-βAla1pP0 conjugates against R. sanguineus infestation in immunized rabbits
| Groups | Reduction percent respect to control of | |||
|---|---|---|---|---|
| Larval yield | Larval viability (%) | Nymph yield | Nymphs’ viability (%) | |
| p64k-Cys1pP0 ( | 57% (73 ± 35)b | 16% (56 ± 7)b | 9% (164 ± 62)a | 24% (74 ± 20)b |
| p64k-βAla1pP0 ( | 17% (139 ± 57)a | 13% (67 ± 26)a | 35% (117 ± 42)b | 5% (92 ± 5)a |
| PBS ( | (168 ± 44)a | (77 ± 18)a | (180 ± 38)a | (97 ± 5)a |
| Groups | Reduction percent respect to control of | |||
| Female yield | Egg mass weight (mg) | Hatchery (%) | ||
| p64k-Cys1pP0 ( | 0% (21 ± 3)a | 3% (96.48 ± 32.22)a | 20% (79 ± 9)b | 81% |
| p64k-βAla1pP0 ( | 0% (21 ± 5)a | 7% (92.34 ± 31.45)a | 15% (84 ± 10)b | 45% |
| PBS ( | (20 ± 4)a | (99.1 ± 30.12)a | (99 ± 2)a | |
E (efficacy) is calculated as 100 × [1−(RL × VL × RN × VN × RA× PA × FE)] where RL, VL, RN, VN, RA, PA, and FE represent the immunogen effect on larvae yield, larvae viability, nymph yield, nymph viability, female yield, egg mass weight, and egg fertility, respectively. Only parameters showing statistical significant differences compared to those in the control group were included in E calculation for each vaccine candidate
In parentheses are shown average ± SD of each recorded parameter
Different letters mean statistically different groups (ANOVA, Bonferroni multiple test, P < 0.05)